Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure

To the Editor: Following two articles in the Journal,1,2 I wish to provide an update on the pricing of statins in Australia and the implications for Pharmaceutical Benefits Scheme (PBS) expenditure. I was prompted to do so by a recent review by the Pharmaceutical Benefits Advisory Committee (PBAC), which was instigated by the Senate when it passed legislation enabling the current pharmaceutical pricing arrangements.3 The purpose of the review was to determine if there was new evidence on whether rosuvastatin and atorvastatin should be included in the existing statins therapeutic group.

A summary of the PBAC review, which was released publicly in August 2012, reaffirmed previous recommendations that atorvastatin and rosuvastatin are more effective than simvastatin in lowering cholesterol levels.4 It also noted that the current evidence did not change the PBAC’s previous advice that only an average price differential of 12.5% between atorvastatin and simvastatin was acceptable.4 This has important implications, as the ex-manufacturer price of simvastatin has fallen significantly…